Responding to a lawsuit by Novartis (NVS), the U.S. Department of Justice has defended Medicare price negotiations, signaling ...
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...
We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
That leap forward came at a sky-high price: more than $2 million per dose, making Zolgensma then the costliest one-time treatment ever. How did a drug rooted, like many, in seed money from the U.S ...
President Trump will still seek a win over the previous administration’s efforts to lower drug prices, Kelly Griffin, director of the health policy and intelligence institute at PwC U.S., said ...
Pharmacy benefits managers, or PBMs, are meant to act as a middleman between drug manufacturers and insurance companies to ...
President Donald Trump likely won't do away with a process that allows Medicare to negotiate drug prices with manufacturers, even as he erases Joe Biden's other policy accomplishments. But Trump ...
His proposal could prevent pharmacy benefit managers from inflating medication costs by banning spread pricing.
As DFL Sen. Amy Klobuchar’s staff facilitated a conversation around staffing at health care and assisted living facilities ...
The start of Donald Trump’s second presidency and Republican control in the 119th Congress raises questions about the future ...
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback